that normal megakaryocytopoiesis was severely impaired nary studies have not found decreased blood levels of Tpo in
Introduction express functional receptors able to bind and internalize Tpo. 20 Both the in vitro growth data and the normal or elevEssential thrombocythemia (ET) is a myeloproliferative disated Tpo blood levels in ET patients, as measured by an ELISA order (MPD) characterized by a sustained thrombocytosis.
assay, 19 suggest that c-mpl receptor expression or function Clinical diagnosis requires the elimination of other myeloprocould be altered in the population of clonal hematopoietic liferative disorders polycythemia vera (PV), chronic myelogencells usually present in ET. ous leukemia and agnogenic myeloid metaplasia, and a care-C-mpl receptor gene expression studies in human and ful search for conditions known to be associated with reactive mouse hematopoietic cells or leukemic cell lines have thrombocytosis.
1,2 The chronic course of ET is associated with revealed the existence of multiple mRNA isoforms ( Figure 1 ) an increased incidence of thrombosis and bleeding. 3 Although whose role in megakaryocytic physiology is unknown: Mpl-S the disease can evolve into acute leukemia, the frequency of (mpl-tr in mouse) a putative soluble receptor form, and Mplleukemia and the role played by cytotoxic drug therapy in the K, a form with a truncated intracytoplasmic domain, only transition to leukemia are still debated. 4 found in human cells, are coexpressed with Mpl-P (mpl 1 or As in other MPDs, clonal proliferation of various type I in mouse), the full-length receptor. [21] [22] [23] [24] Two other varihematopoietic lineages including granulocytes, megakaryoant forms with in-frame deletions of the mRNA 5Ј end have cytes, erythroblasts and monocytes has been demonstrated in been described in mouse cell lines with megakaryocytic feamost cases of ET. [5] [6] [7] The mechanisms of the proliferative tures. 25, 26 These deletions mapped to the first c-mpl domain, advantage predominantly affecting megakaryocytes in vivo and one of them (mpl type II) is associated with a higher proare unclear. In vitro, endogenous erythroid colony formation, liferative activity in transfection assays than the predominantly ie in absence of added erythropoietin, can be demonstrated expressed transcript mpl type I. 26, 27 in 60% of patients' blood or bone marrow (BM) samples, as Based on these different results, we analyzed the relative is the case in PV. 8, 9 Similarly, autonomous growth of megakarexpression of c-mpl isoforms in platelets derived from ET yocytic colonies can be observed in blood or BM samples patients and searched for c-mpl mutations in those patients derived from ET patients in the absence of added aplastic with unexplained high platelet counts. serum or growth factors such as interleukin 3, 6 (IL-3, IL-6) and GM-CSF. expression. C-mpl cDNA was sequenced from one of these patients, and from three other ET patients. Restriction polystart procedure, in the presence of 5% DMSO, was used only for the amplification of the Mpl P,K, and S isoforms in a single morphisms were then analyzed in 44 ET patients. All selected patients were female patients and had blood samples separreaction. Reaction products were analysed on 2% agarose gels stained with EtBr or acrylamide 6% denaturating gels for ated for X-chromosome inactivation studies of granulocytes, lymphocytes, and platelets as previously described. 7 All analysis of radioactive PCR products. Estimation of the relative intensities of each PCR product was obtained by addition of patients gave their informed consent for use of this material for clinical research.
2 Ci of 32 P-dCTP per reaction, and the dried gel was counted on a Packard Instant Imager (Packard Instruments, Rungis, C-mpl mRNAs expression was also studied in five healthy volunteers, and the c-mpl cDNA sequenced from one. RestricFrance) using the supplier's software. tion polymorphism studies were performed on 30 control subjects. RNA samples were also prepared from an HEL cell line subculture grown in standard conditions, and from two CD34 + Cloning and sequencing procedures purified cell fractions derived from human leukapheresis products.
PCR products were cloned into the Promega (Charbonnieres, France) pGEM-T vector after ligation of gel purified PCR fragPlatelets were recovered from 50 ml of blood drawn on sodium citrate tubes (Vacutainer; Poly Labo, Strasbourg, ments with T4 DNA ligase and transformation of E. coli DH5␣ (Library Efficiency DH5␣, Life Technology). The sequence of France). Platelet rich plasma (PRP) was obtained after centrifugation at 900 r.p.m. for 15 min. The platelets themselves two independent clones was determined with a T7 DNA Polymerase kit (Pharmacia Biotech, Orsay, France). were recovered by centrifugation at 1400 r.p.m., the pellet being directly processed for RNA preparation as described 7 or kept at −80°C. Leukocyte DNA was prepared by conventional methods. 7 C-mpl mutation search and polymorphism analysis C-mpl mutation search was done by direct sequencing of overlapping PCR c-mpl cDNA fragments, using a DNA ana-C-DNA primers selection and reverse transcription conditions lyser (Genome Express, Grenoble, France). PCR conditions were the same as previously described. D1a, D1b and D1c are used to amplify the region coding for the signal peptide All primers were designed from the published Mpl-K and Mpl-P sequences (Genbank No. M90102 and M90103) 21 ,24 using and the first cytokine receptor domain of Mpl. D2a, D2b, D2c and D2d amplify the second cytokine receptor domain, PKa the Oligo 4 program. Primer sequences and hybridation temperatures are listed in Table 1 . Location of primers for mRNAs and Pb the intra-cellular domain of the Mpl-P isoform, PKa and Kb the same region of Mpl-K (Figure 2 ). expression analysis is shown on the c-mpl exon map ( Figure  1 ).
Restriction analysis was performed after amplification of platelet cDNA (Mpl-P) or blood leukocyte DNA (Mpl-K) using Platelet cDNA was typically obtained from total platelet RNA, using random hexanucleotides and an M-MLV reverse primers located on each side of polymorphisms detected by the sequencing (PMa and PMb for Mpl-P, KMa and KMb for transcriptase as recommended by the supplier (Life Technology, Cergy Pontoise, France).
Mpl-K). Amplified products were then digested by HindIII for Mpl-P, and KpnI for Mpl-K, according to the supplier's instructions (Life Technology) and analyzed on agarose gels.
PCR assays
All reactions were performed in a Hybaid Thermal Reactor Results (Schleicher and Schuell, Cera Labo, Ecquevilly, France), in a 50 l volume with 4 l of platelet cDNA, 12.5 pmoles of priNew isoforms of c-mpl mers, 0.5 mm dNTP, 1.5 mm magnesium chloride, 0.2 units of Taq polymerase (Appligene, Strasbourg, France). Thirty-five
We used the primer PK6 located in the 5Ј end of exon 8 and two primers PS and 2K (Figure 1 ) simultaneously to amplify amplification cycles were performed (15 s at 94°C for denaturation, 20 s for annealing, 18 s at 70°C for elongation). A hot the three known isoforms Mpl-P, Mpl-S and Mpl-K. In addition Position is given according to the published sequences. Isoforms, c-mpl isoforms that can be amplified with the primer; s, sense; as, anti-sense.
Figure 2
Location of primers used to sequence MPL-P and MPL-K.
to the Mpl-P, K and S fragments of expected size (516, 413 and 258 bp, respectively), two additional bands were observed on denaturating gels (Figure 3 ) in all platelet samples analyzed. Each additional band was cloned in pGEM-T and Search for mutations sequenced. As indicated in Figure 4 , both fragments were likely to result from the use of an alternative acceptor splicing Four platelet cDNA samples from ET patients were amplified with primers designed to generate overlapping fragments of site AG*CTG (nucleotides 1380-1384) in exon 9. The resulting 72 bp deletion in both Mpl-P2 and Mpl-K2 should the Mpl-P and Mpl-K isoforms (Figure 2) . In all samples, the sequence of Mpl-K cDNA differed from the published theoretically lead to a 24 amino acid (aa) deletion of the second c-mpl domain in the same reading frame, starting 38 sequence: GGCC was repeatedly found at position 1616 instead of CG. The accuracy of our sequencing was checked aa upstream of the WSSWS box. The Mpl-P2 isoform was also expressed in the HEL cell line and in CD34 + cells. Mpl-K2 by restriction analysis using StuI which cuts the GGCC sequence. According to this new sequence, the predicted aa was expressed in HEL cells while an additional unidentified band was observed in both HEL and CD34
+ cells (Figure 3) . sequence of Mpl-K intracytoplasmic domain is 30 aa shorter than the published sequence ( Figure 5 ). Using a different set of primers, we were unable to detect isoforms of the first cytokine receptor domain, in human platelets A neutral transition (A→G in position 690) was detected in one patient. This transition is associated with the loss of a samples or in the HEL or DAMI cell lines (data not shown).
HindIII restriction site. Digestion of amplified fragments indicated that this sequence variation was present at the heterozygous state in one of five ET samples but also in one of nine
Relative expression of these isoforms control samples. A second transition (C→T) was found in one ET sample in As shown in Figure 3 , Mpl-P is the major c-mpl transcript in human platelets derived from normal subjects or ET patients.
position 1570 of the Mpl-K sequence. This mutation is predicted to be responsible for an Arg for Cys change in the intraAll isoforms were similarly expressed in control and ET platelet samples. cytoplasmic region. As the mutation is associated with the loss of a KpnI restriction site, 40 additional blood DNA samples A similar proportion of Mpl-P, Mpl-K and Mpl-P2 was expressed in platelets, CD34
+ cells and the HEL cell line. derived from ET patients and 30 DNA from blood donors were added growth factors cannot be explained by the existence of
